Dovato (dolutegravir/lamivudine) for HIV-1 Infection:

(FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen.

Lamivudine structure.svg
Lamivudine
Dolutegravir Structural Formula Illustration
Dolutegravir sodium

Leave a Reply

Your email address will not be published. Required fields are marked *